Zvrko, Elvir (24072434300)Elvir (24072434300)ZvrkoMikic, Anton (22941219500)Anton (22941219500)MikicVuckovic, Ljiljana (26428630400)Ljiljana (26428630400)VuckovicDjukic, Vojko (6701658274)Vojko (6701658274)DjukicKnezevic, Milan (56729012600)Milan (56729012600)Knezevic2025-06-122025-06-122009https://doi.org/10.1016/j.otohns.2009.07.001https://www.scopus.com/inward/record.uri?eid=2-s2.0-70349484441&doi=10.1016%2fj.otohns.2009.07.001&partnerID=40&md5=6ea345e3ecfc37f9041510e4a6c20df6https://remedy.med.bg.ac.rs/handle/123456789/10511Objective: To examine immunohistochemical expression of CD105 among patients with laryngeal cancer and investigate the prognostic significance of CD105-assessed microvessel density (MVD). Study Design: Cross-sectional study. Setting: University hospital. Subjects and Methods: The study comprised 80 patients with laryngeal squamous cell carcinoma who underwent complete excision. Clinicopathological data were collected retrospectively. Immunohistochemical analysis was performed with CD105 (endoglin) antibody. Positive-stained microvessels for CD105 were counted on hot spots of tumors at ×200 magnification. Results: Average CD105-assessed MVD in considered laryngeal squamous cell carcinomas (SCCs) was 12.9 (SD 3.84). High expression of CD105 correlated significantly with advanced T (tumor) classification (P = 0.008), advanced TNM (tumor, node, metastasis) stage (P = 0.001), tumor recurrence (P = 0.001), and age ≥65 years (P = 0.026). The multivariate logistic regression showed that a high CD105+ MVD (odds ratio [OR] 4.27; P = 0.019) and advanced TNM stage (OR 3.72; P = 0.047) were independent markers of tumor recurrence. High MVD, advanced clinical stage, the presence of lymph node metastasis at the time of diagnosis, and age <66 years were associated with worse disease-free survival. Cox regression analysis revealed that expression of CD105 (P = 0.016) and advanced clinical stage (P = 0.05) were the independent factors for disease-free survival. Conclusion: The present results suggest that MVD evaluation with CD105 is a promising prognostic factor for the outcome of patients with laryngeal SCC. CD105-assessed MVD could help to identify patients with more aggressive disease and increased risk of developing malignancy recurrence after treatment. © 2009 American Academy of Otolaryngology-Head and Neck Surgery Foundation.